Rheumatology Practice Management
Subscribe to Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or e‑Newsletters.

RPM e-Newsletter
RPM print publication

ASCO Genitourinary Cancers Highlights

Combining cabozantinib (Cabometyx) with atezolizumab (Tecentriq) induced responses in 32% of patients with metastatic castration-resistant prostate cancer (CRPC) who had soft-tissue progression after previous novel hormonal therapy. Read More ›

De-escalating chemotherapy based on a negative positron emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic semin­oma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium. Read More ›

MicroRNAs have all the characteristics to be a potential game changer as a biomarker in germ-cell tumors (originating in the testes, ovaries, and a few other sites), with high sensitivity, specificity, and clinical validity in pilot studies, said Lucia Nappi, MD, PhD, Medical Oncologist, British Columbia Cancer, Vancouver Centre, Canada, at the 2020 Genitourinary Cancers Symposium. Read More ›